Prescient Therapeutics Limited (ASX:PTX)
Australia flag Australia · Delayed Price · Currency is AUD
0.0460
-0.0010 (-2.13%)
Aug 1, 2025, 3:59 PM AEST

Prescient Therapeutics Company Description

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.

Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway.

The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014.

Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Prescient Therapeutics Limited
Prescient Therapeutics logo
CountryAustralia
Founded1986
IndustryBiotechnology
SectorHealthcare
Employees3
CEOJames McDonnell

Contact Details

Address:
Suite 2
Melbourne, 3000
Australia
Phone61 3 9692 7222
Websiteptxtherapeutics.com

Stock Details

Ticker SymbolPTX
ExchangeAustralian Securities Exchange
Fiscal YearJuly - June
Reporting CurrencyAUD
ISIN NumberAU000000PTX3
SIC Code2836

Key Executives

NamePosition
James McDonnellChief Executive Officer
Melanie Jaye Leydin B.Bus, C.A., CAChief Financial Officer and Company Secretary
Dr. Rebecca TunstallChief Operating Officer
Dr. Marissa Lim M.B.A., MBBSChief Medical Officer